Trials / Recruiting
RecruitingNCT06624098
Early Transjugular Intrahepatic Portosystemic Shunt for Advanced Hepatocellular Carcinoma
Early Transjugular Intrahepatic Portosystemic Shunt for Advanced Hepatocellular Carcinoma With Main Trunk Portal Vein Tumor Thrombus Induced Gastrointestinal Bleeding: a Multicenter Phase II Study
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 22 (estimated)
- Sponsor
- Sun Yat-sen University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Hepatocellular carcinoma (HCC) with main trunk portal vein tumor thrombus (PVTT) has poor prognosis. The main lethiferous factor is the upper gastrointestinal hemorrhage by PVTT-related portal hypertension. Studies have proven that early transjugular intrahepatic portosystemic shunt (TIPS) with 72 hours after acute variceal bleeding is effective.
Detailed description
Portal hypertension by main trunk portal vein tumor thrombus (PVTT) is a severe disease. Patients usually die of gastrointestinal hemorrhage rather than tumor progression. It is vital to prevent the portal hypertension. Transjugular intrahepatic portosystemic shunt (TIPS) is an effective method to alleviate the portal pressure. Then the risk of gastrointestinal hemorrhage is decreased which provides an opportunity for system therapy. Studies have proven that early transjugular intrahepatic portosystemic shunt (TIPS) with 72 hours after acute variceal bleeding is effective for cirrhosis induced portal hypertension. However, the PVTT induced portal hypertension still needs clinical evidence. In this study, the investigators explore the early TIPS for advanced hepatocellular carcinoma with main trunk portal vein tumor thrombus induced acute variceal bleeding. The investigators aim to added clinical evidence for this subtype of advanced HCC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Early TIPS | TIPS was performed within 72 hours after the endoscopic hemostasis. |
Timeline
- Start date
- 2024-10-01
- Primary completion
- 2025-12-30
- Completion
- 2026-06-30
- First posted
- 2024-10-02
- Last updated
- 2024-10-02
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06624098. Inclusion in this directory is not an endorsement.